Dr. Ketan K. Badani on how genomic tests help facilitate patient discussions

“One of the toughest parts about having a discussion with a patient about low-risk or early-stage prostate cancer…is actually deciding what might be best for that individual patient,” says Ketan K. Badani, MD.

In this video, Ketan K. Badani, MD, discusses how genomic tests such as Oncotype DX help him discuss treatment options for patients with low-risk or early-stage prostate cancer. Badani is a professor of urology at Icahn School of Medicine at Mount Sinai, vice chairman of urology and robotic operations at Mount Sinai Health System, director of robotic surgery at Mount Sinai West, and the director of the Comprehensive Kidney Cancer Program At Mount Sinai Health System, New York.